



What to expect from a US IPO
Life Sciences Virtual Panel Event

Thursday 3 December 2020
15:00 - 16:30 GMT

It's no secret that a US IPO is on the agenda of the boards of many UK life sciences businesses. The market is currently hot and COVID-19 has not slowed the appetite of US investors for life sciences stocks.

According to our recent [Global IPO Trends report](#), Q3 2020 bucked the traditionally slow IPO period as the markets were awash with liquidity resulting in the most active third quarter in the last 20 years by proceeds, and the second highest third quarter by deal numbers. There were 159 healthcare IPOs which raised US\$33.3 billion.

We are regularly receiving calls from UK life sciences businesses who are keen to prepare for a US IPO and to understand what it means, what to expect, what the challenges are and how to deal with them. We have assembled a panel of expert speakers to discuss their perspectives. Our panel will shine a light on what a US IPO means for companies, CFOs, their boards and investors, what to look out for, and how to most effectively prepare.

Each of our speakers will give a short talk on their recent experiences and views followed by a panel discussion and Q&A.

RSVP [here to secure your place](#). We hope you can join us for this virtual panel.

Our panel



Dr Rob Quinn, CFO, Silence Therapeutics

Rob is the CFO of Silence Therapeutics plc and recently led Silence from AIM to being dual listed with its listing on NASDAQ in September 2020. Rob is a chartered accountant and former scientist. He is one of the first UK CFOs to execute a US listing in a virtual world.



Don Munoz, CFO, Nucana plc

Don is the CFO of Nucana plc and led this previously private company through its IPO on NASDAQ in 2017. Don also has an MBA and extensive background in US healthcare investment banking.



Dr Andy Richards CBE

Andy is a serial entrepreneur and investor with an established track record in founding and scaling up innovative Biotech and Healthtech companies. He is a chairman and non-executive director of numerous life sciences boards and advisor to several investment funds including Cambridge Innovation Capital and the UCL Technology Fund.



Laura Segert, US Capital Markets Partner, EY

Laura is a US CPA and has extensive experience in supporting UK life sciences and other businesses undertake cross border IPOs onto the US market.



Adrian Bennett PhD, Life Sciences and Assurance Partner, EY

The panel will be hosted and chaired by Adrian, an experienced adviser to fast growing technology and global life-sciences and pharma businesses including start-ups, AIM and Main Market and US listed companies.